Literature DB >> 26216558

Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms.

Giuseppe Valeriani1, Ornella Corazza2, Francesco Saverio Bersani1,2, Claudia Melcore1, Antonio Metastasio3, Giuseppe Bersani4, Fabrizio Schifano2.   

Abstract

OBJECTIVE: The pharmacological self-management of novel psychoactive substance (NPS)-induced psychopathological consequences represents a fast growing phenomenon. This is facilitated by the frequent sharing of NPS intake experiences online and by the ease of access to a range of psychotropic medications from both the online and street market. Olanzapine is anecdotally reported by Web users to be the most frequent self-prescribed medication to cope with NPS-induced psychoses. Hence, we aimed here at better assessing olanzapine use/misuse for this purpose.
METHODS: Exploratory qualitative searches of 163 discussion fora/specialized websites have been carried out in four languages (English, German, Spanish, and Italian) in the time frame November 2012-2013.
RESULTS: Most NPS-users allegedly self administer with olanzapine to manage related psychotic crises/"bad trips". This may be typically taken only for a few days, at a dosage range of 5-50 mg/day.
CONCLUSIONS: Only a few research studies have formally assessed the effectiveness of olanzapine and indeed of other second-generation antipsychotics to treat NPS-induced psychosis. Olanzapine was suggested here from a range of pro drug websites as being the "ideal" molecule to terminate "bad trips". Health professionals should be informed about the risks related to olanzapine misuse.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  drug misuse; drug-induced psychoses; novel psychoactive substances; olanzapine; online reports

Mesh:

Substances:

Year:  2015        PMID: 26216558     DOI: 10.1002/hup.2431

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  11 in total

1.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

Review 2.  Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

Authors:  Aryan Sarparast; Kelan Thomas; Benjamin Malcolm; Christopher S Stauffer
Journal:  Psychopharmacology (Berl)       Date:  2022-03-07       Impact factor: 4.415

3.  The clinical challenges of synthetic cathinones.

Authors:  Fabrizio Schifano; Flavia Napoletano; Davide Arillotta; Caroline Zangani; Liam Gilgar; Amira Guirguis; John Martin Corkery; Alessandro Vento
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

4.  When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use.

Authors:  Kirsten E Smith; Jeffery M Rogers; Justin C Strickland; David H Epstein
Journal:  Am J Drug Alcohol Abuse       Date:  2021-04-28       Impact factor: 3.912

Review 5.  The Benefits of Olanzapine in Palliating Symptoms.

Authors:  Mellar P Davis; Gareth J Sanger
Journal:  Curr Treat Options Oncol       Date:  2020-11-26

Review 6.  Adverse Psychiatric Effects Associated with Herbal Weight-Loss Products.

Authors:  F Saverio Bersani; Marialuce Coviello; Claudio Imperatori; Marta Francesconi; Christina M Hough; Giuseppe Valeriani; Gianfranco De Stefano; Flaminia Bolzan Mariotti Posocco; Rita Santacroce; Amedeo Minichino; Ornella Corazza
Journal:  Biomed Res Int       Date:  2015-09-17       Impact factor: 3.411

Review 7.  Following "the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries.

Authors:  Eduardo Cinosi; Giovanni Martinotti; Pierluigi Simonato; Darshan Singh; Zsolt Demetrovics; Andres Roman-Urrestarazu; Francesco Saverio Bersani; Balasingam Vicknasingam; Giulia Piazzon; Jih-Heng Li; Wen-Jing Yu; Máté Kapitány-Fövény; Judit Farkas; Massimo Di Giannantonio; Ornella Corazza
Journal:  Biomed Res Int       Date:  2015-11-10       Impact factor: 3.411

8.  Transitioning Bodies. The Case of Self-Prescribing Sexual Hormones in Gender Affirmation in Individuals Attending Psychiatric Services.

Authors:  Antonio Metastasio; Attilio Negri; Giovanni Martinotti; Ornella Corazza
Journal:  Brain Sci       Date:  2018-05-14

Review 9.  Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review.

Authors:  Fabrizio Schifano; Stefania Chiappini; John M Corkery; Amira Guirguis
Journal:  Brain Sci       Date:  2018-04-22

10.  Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues.

Authors:  Stefania Bonaccorso; Antonio Metastasio; Angelo Ricciardi; Neil Stewart; Leila Jamal; Naasir-Ud-Dinn Rujully; Christos Theleritis; Stefano Ferracuti; Giuseppe Ducci; Fabrizio Schifano
Journal:  Brain Sci       Date:  2018-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.